For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Histone Deacetylase 1 (HDAC1 or EC 184.108.40.206) - Pipeline Review, H2 2017
Histone Deacetylase 1 (HDAC1 or EC 220.127.116.11) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 1 (HDAC1 or EC 22.214.171.124) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 1, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Genetic Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Neuroblastoma, Solid Tumor, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Becker Muscular Dystrophy, Bone Disorders, Burkitt Lymphoma, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), CNS Lymphoma, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Leukemias, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Skin Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer.
Furthermore, this report also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 126.96.36.199) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 188.8.131.52)
- The report reviews Histone Deacetylase 1 (HDAC1 or EC 184.108.40.206) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 220.127.116.11) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 1 (HDAC1 or EC 18.104.22.168) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 22.214.171.124) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 126.96.36.199)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 188.8.131.52) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope